1204918-72-8

Basic information

• Product Name: SB1317
• Synonyms: SB1317;TG02;SB1317 (Double bond E);TG02 (Double bond E);SB1317 (TG-02);VXBAJLGYBMTJCY-UHFFFAOYSA-N
• CAS NO: 1204918-72-8
• Molecular Formula: C23H24N4O
• Molecular Weight: 372.46286
• Product Categories: Inhibitors
• Mol File: 1204918-72-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: SB1317(CAS DataBase Reference)
• NIST Chemistry Reference: SB1317(1204918-72-8)
• EPA Substance Registry System: SB1317(1204918-72-8)

Safety Data

• Hazardous Substances Data: 1204918-72-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
SB1317 is used as a cyclin-dependent kinase inhibitor (CDK inhibitor) for the treatment of chronic lymphocytic leukemia. It plays a crucial role in regulating cell cycle progression and has shown potential in targeting cancer cells, thereby offering a promising therapeutic approach for patients suffering from this condition.
Used in Chemical Industry:
In the chemical industry, SB1317 may be utilized for various purposes, such as a catalyst, intermediate, or additive, depending on its specific chemical properties and reactivity. Its applications could range from enhancing the efficiency of chemical reactions to improving the performance of certain materials.

Upstream product

• 937271-43-7 3-(2-chloropyrimidine-4-yl)phenol 
• 937271-45-9 4-(3-(but-3-en-1-yloxy)phenyl)-2-chloropyrimidine 
• 87199-18-6 3-hydroxyphenylboronic acid 
• 937271-61-9 C₂₅H₂₈N₄O 
• 156682-54-1 3-(benzyloxy)phenylboronic acid 
• 99-61-6 3-nitro-benzaldehyde 
• 937271-55-1 allylmethyl-(3-nitrobenzyl)amine 
• 937271-56-2 3-[(allylmethylamino)methyl]phenylamine 

Relevant articles and documents

Polymorphic form of TG02

The present disclosure provides crystalline polymorphic forms of TG02 free base and TG02 acid addition salts, pharmaceutical compositions comprising crystalline polymorphic forms of TG02 free base and TG02 acid addition salts, and methods of treating cancer and other diseases in a patient with crystalline polymorphic forms of TG02 free base and TG02 acid addition salts.

Acid mediated ring closing metathesis: A powerful synthetic tool enabling the synthesis of clinical stage kinase inhibitors

The powerful olefin metathesis reaction was employed for the construction of late-phase clinical agents SB1317 and SB1518. In both cases RCM seems to proceed only in the presence of an acid and to predominantly furnish trans isomers. In case of SB1518 it proceeded in the presence of acid HCl, while for SB1317, it mainly proceeds in the presence of TFA (trifluroacetic acid).

Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5, 7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27) ,9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer

Herein, we describe the design, synthesis, and SAR of a series of unique small molecule macrocycles that show spectrum selective kinase inhibition of CDKs, JAK2, and FLT3. The most promising leads were assessed in vitro for their inhibition of cancer cell proliferation, solubility, CYP450 inhibition, and microsomal stability. This screening cascade revealed 26h as a preferred compound with target IC50 of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively. Pharmacokinetic (PK) studies of 26h in preclinical species showed good oral exposures. Oral efficacy was observed in colon (HCT-116) and lymphoma (Ramos) xenograft studies, in line with the observed PK/PD correlation. 26h (SB1317/TG02) was progressed into development in 2010 and is currently undergoing phase 1 clinical trials in advanced leukemias and multiple myeloma.